Niraparib

(asked on 11th February 2021) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what plans he has to make niraparib available through the NHS for treatment of ovarian cancer.


Answered by
Jo Churchill Portrait
Jo Churchill
Minister of State (Department for Work and Pensions)
This question was answered on 2nd March 2021

In July 2018, the National Institute for Health and Care Excellence (NICE) published guidance on niraparib. NICE recommended niraparib for use within the Cancer Drugs Fund (CDF) as an option for treating relapsed, platinum-sensitive high-grade serious epithelial ovarian, fallopian tube or primary peritoneal cancer, that has responded to the most recent course of platinum-based chemotherapy in adults who have had two or more courses of platinum-based chemotherapy. Niraparib is now available to National Health Service patients through the CDF in line with this guidance.

In addition, NICE issued final draft guidance in January 2021 that recommends niraparib for use within the CDF for the maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. Niraparib is funded through the CDF for eligible patients in line with NICE’s final draft recommendations.

Reticulating Splines